Core Viewpoint - The announcement details the stock listing related to the equity incentive plan of Sino Medical Science Technology Co., Ltd., including the number of shares, listing date, and the decision-making process for the stock allocation [2][3][15]. Group 1: Stock Listing Details - The type of stock listing is for equity incentive shares, with a total of 1,904,000 shares to be listed [2]. - The listing date for the shares is set for January 22, 2026 [3][13]. - The shares are part of the 2022 restricted stock incentive plan, with the first allocation of the second vesting period recently completed [3][9]. Group 2: Decision-Making Process - The decision-making process for the stock allocation involved multiple meetings of the board and supervisory board, with independent directors providing clear consent [4][6][8]. - The company conducted a public notice period for the proposed incentive recipients, during which no objections were raised by employees [5][6]. Group 3: Stock Allocation and Impact - A total of 7 individuals will receive the allocated shares [12]. - The new shares will increase the total share capital from 416,048,000 to 417,952,000 shares, representing approximately 0.4576% of the total shares before the allocation [14][15]. - The allocation is not expected to have a significant impact on the company's recent financial status or operating results [15].

12月25日，赛诺医疗涨5.12%，截至发稿，报18.69元/股，成交2.13亿元，换手率2.83%，总市值77.76亿 元。 国泰海通量化选股混合发起A（016466）基金经理为胡崇海。 资料显示，赛诺医疗科学技术股份有限公司位于天津开发区第四大街5号泰达生物医药研发大厦A区3 层，成立日期2007年9月21日，上市日期2019年10月30日，公司主营业务涉及高端介入医疗器械研发、 生产、销售,产品管线涵盖心血管、脑血管、结构性心脏病等介入治疗重点领域。主营业务收入构成 为：支架59.76%，球囊32.68%，其他7.56%。 从基金十大重仓股角度 数据显示，国泰海通资管旗下1只基金重仓赛诺医疗。国泰海通量化选股混合发起A（016466）三季度 持有股数44.43万股，占基金净值比例为0.89%，位居第一大重仓股。根据测算，今日浮盈赚取约40.43 万元。 国泰海通量化选股混合发起A（016466）成立日期2022年8月18日，最新规模5.99亿。今年以来收益 33.18%，同类排名2673/8087；近一年收益30.85%，同类排名2722/8071；成立以来收益47.24%。 截至发稿，胡崇海累计任职时 ...

12月19日，赛诺医疗涨5.09%，截至发稿，报18.39元/股，成交1.69亿元，换手率2.25%，总市值76.51亿 元。 国泰海通量化选股混合发起A（016466）基金经理为胡崇海。 截至发稿，胡崇海累计任职时间4年6天，现任基金资产总规模136.84亿元，任职期间最佳基金回报 68.39%， 任职期间最差基金回报-0.17%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，赛诺医疗科学技术股份有限公司位于天津开发区第四大街5号泰达生物医药研发大厦A区3 层，成立日期2007年9月21日，上市日期2019年10月30日，公司主营业务涉及高端介入医疗器械研发、 生产、销售,产品管线涵盖心血管、脑血管、结构性心脏病等介入治疗重点领域。主营业务收入构成 为：支架59.76%，球囊32.68%，其他7.56%。 从基金十大重仓股角度 数据显示，国泰海通资管旗下1只基金重仓赛诺医疗。国泰海通量化选股混合发起A（016466）三季度 持有股数44 ...

12月19日，赛诺医疗盘中上涨2.00%，截至09:54，报17.85元/股，成交3045.69万元，换手率0.41%，总 市值74.26亿元。 赛诺医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、小盘、QFII 持股、融资融券、专精特新等。 截至9月30日，赛诺医疗股东户数2.94万，较上期增加164.74%；人均流通股14170股，较上期减少 62.23%。2025年1月-9月，赛诺医疗实现营业收入3.64亿元，同比增长14.24%；归母净利润2111.80万 元，同比增长293.46%。 分红方面，赛诺医疗A股上市后累计派现4100.00万元。近三年，累计派现0.00元。 责任编辑：小浪快报 资金流向方面，主力资金净流入5.67万元，大单买入402.49万元，占比13.22%，卖出396.82万元，占比 13.03%。 赛诺医疗今年以来股价涨82.89%，近5个交易日跌0.22%，近20日跌0.56%，近60日跌39.08%。 今年以来赛诺医疗已经7次登上龙虎榜，最近一次登上龙虎榜为10月29日，当日龙虎榜净买入-5123.31 万元；买入总计2.04亿元 ，占总成交额比1 ...

Core Viewpoint - Sino Medical has shown significant stock performance with a year-to-date increase of 102.66%, despite recent fluctuations in the stock price [1][2] Group 1: Stock Performance - As of November 14, Sino Medical's stock price reached 19.78 CNY per share, with a market capitalization of 8.229 billion CNY [1] - The stock experienced a net inflow of 8.0564 million CNY from major funds, with large orders accounting for 20.37% of total buy orders [1] - The stock has seen a decline of 29.83% over the past 20 days and 34.93% over the past 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Sino Medical reported a revenue of 364 million CNY, reflecting a year-on-year growth of 14.24% [2] - The net profit attributable to the parent company was 21.118 million CNY, marking a substantial increase of 293.46% year-on-year [2] - The company has distributed a total of 41 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [2] Group 3: Company Overview - Sino Medical, established on September 21, 2007, specializes in the research, production, and sales of high-end interventional medical devices [1] - The company's product line includes key areas such as cardiovascular, cerebrovascular, and structural heart disease interventions, with stents contributing 59.76% and balloons 32.68% to its revenue [1][2] - As of September 30, the number of shareholders increased to 29,400, with an average of 14,170 circulating shares per shareholder [2]

Group 1 - The core viewpoint of the news is that Sino Medical has shown significant stock performance with a year-to-date increase of 177.56%, despite recent declines in the short term [1] - As of September 29, Sino Medical's stock price was 27.09 CNY per share, with a total market capitalization of 11.271 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 1.6928 million CNY, with large orders contributing significantly to the buying activity [1] Group 2 - For the first half of 2025, Sino Medical reported a revenue of 240 million CNY, reflecting a year-on-year growth of 12.53%, and a net profit attributable to shareholders of 13.8416 million CNY, which is a substantial increase of 296.54% [2] - The number of shareholders increased to 11,100, with an average of 37,515 circulating shares per person, indicating a slight rise in shareholder engagement [2] Group 3 - Since its A-share listing, Sino Medical has distributed a total of 41 million CNY in dividends, although there have been no dividends paid in the last three years [3]

Group 1 - The core viewpoint of the news is that Sino Medical has experienced a significant stock price increase of 194.16% year-to-date, but has recently faced a decline of 8.60% over the past five trading days and 12.20% over the past twenty days [1] - As of September 19, Sino Medical's stock price was reported at 28.71 CNY per share, with a total market capitalization of 11.945 billion CNY [1] - The company has seen a net outflow of main funds amounting to 41.1372 million CNY, with large orders showing a buy of 45.0039 million CNY and a sell of 63.0312 million CNY [1] Group 2 - For the first half of 2025, Sino Medical achieved operating revenue of 240 million CNY, representing a year-on-year growth of 12.53%, and a net profit attributable to shareholders of 13.8416 million CNY, which is a significant increase of 296.54% [2] - The company has a total of 11,100 shareholders as of June 30, with an average of 37,515 circulating shares per shareholder, indicating a slight increase in shareholder engagement [2] Group 3 - Since its A-share listing, Sino Medical has distributed a total of 41 million CNY in dividends, but has not paid any dividends in the last three years [3]

Company Overview - Sino Medical Science Technology Co., Ltd. is located in Tianjin and was established on September 21, 2007, with its listing date on October 30, 2019 [1] - The company specializes in the research, production, and sales of high-end interventional medical devices, focusing on cardiovascular, cerebrovascular, and structural heart disease treatment areas [1] - The revenue composition of the main business includes stents (59.76%), balloons (32.68%), and others (7.56%) [1] Financial Performance - As of June 30, the number of shareholders increased to 11,100, a rise of 0.42%, with an average of 37,515 circulating shares per person, up by 0.21% [2] - For the first half of 2025, the company achieved a revenue of 240 million yuan, representing a year-on-year growth of 12.53%, while the net profit attributable to shareholders was 13.84 million yuan, up by 296.54% [2] Stock Performance - On August 29, the stock price of Sino Medical fell by 2.10% to 31.20 yuan per share, with a trading volume of 294 million yuan and a turnover rate of 2.20%, resulting in a total market capitalization of 12.981 billion yuan [1] - Year-to-date, the stock price has increased by 219.67%, with a recent decline of 4.59% over the last five trading days, but a rise of 112.97% over the last 20 days and 174.41% over the last 60 days [1] - The company has appeared on the daily trading leaderboard six times this year, with the most recent occurrence on August 22 [1] Dividend Information - Since its A-share listing, Sino Medical has distributed a total of 41 million yuan in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - The stock of Sino Medical Science Technology Co., Ltd. experienced a significant decline, with a cumulative drop of 30% over three consecutive trading days, indicating abnormal trading fluctuations [1][7]. Group 1: Stock Trading Fluctuations - The company's stock closed at 32.70 yuan per share as of August 22, 2025, with recent price volatility exceeding that of most peers and the Shanghai Composite Index [3][9]. - The rolling price-to-earnings ratio of the company is reported at 2318.77, significantly deviating from the industry average of 34.84 [3][9]. - The trading turnover rates for August 20, 21, and 22, 2025, were 16.56%, 19.01%, and 14.54%, respectively, indicating a notable increase compared to previous levels [3][9]. Group 2: Company Announcements and Developments - The company disclosed that it received conditional approval from the FDA for its new drug-eluting stent system on July 22, 2025, and announced the breakthrough medical device certification for its subsidiary's products on August 7, 2025 [2][8]. - The COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter received FDA breakthrough device designation, which provides expedited review and support for product development [4][10]. - The blood flow-directed mesh stent system, AUCURA, obtained domestic medical device registration in May 2025 and was selected for a procurement project in Guangdong province, set to commence on September 1, 2025 [5][12]. Group 3: Financial Performance - The company reported a net profit of -39.63 million yuan for 2023 and 1.38 million yuan for the first half of 2025, indicating a recovery from previous losses [6][13]. - The financial results highlight the company's ongoing efforts to stabilize and improve its profitability amidst market fluctuations [6][13].

Group 1 - The medical device sector has shown signs of recovery, with the medical device ETF (562600) rising by 0.83% and leading stock Meihao Medical surging by 18% [1] - In the past five trading days, the medical device ETF (562600) has seen net inflows on four occasions, accumulating a total of 40.2 million yuan, while in the last ten trading days, there were net inflows on nine days, totaling 79.66 million yuan [1] - As of August 20, 2023, 95% of the 131 companies in the A-share medical device sector have experienced stock price increases over the past month, with a notable 207.59% cumulative price increase for Sainuo Medical Technology Co., Ltd. [1] Group 2 - According to a report by CITIC Securities, the A-share Shenwan Medical Device Index has been in decline for the past four years due to policy factors, but has started to rebound since early 2025 [2] - The report anticipates that with policy easing, procurement clearing, corporate strategic transformations, and international business expansion, many companies will see performance and valuation recovery, with high growth expected in the second half of 2025 and 2026 [2] - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All-Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2]